Background-Endothelial dysfunction and monocyte migration are key events in the pathogenesis of atherosclerosis.
Clinical Perspective on p 57
Vascular endothelium provides a selective barrier controlling the traffic of plasma proteins and circulating cells across the blood vessel wall. The integrity of this barrier is maintained on the basis of dynamic interactions between endothelial cytoskeleton, cell-cell junctions, and cell-matrix focal adhesions. Endothelial barrier dysfunction has been impli-cated as an important mechanism underlying many diseases or injurious conditions associated with inflammation, 2 where inflammatory mediators activate diverse signaling pathways in the endothelium leading to widened intercellular space allowing the passage of macromolecules and cells.
Activation of cytoskeletal contractile machinery is critical for cell motility (leukocyte migration) and cell-cell adhesionbased barrier properties (endothelial permeability). In endothelial monolayers, cytoskeleton contraction produces a centripetal force that counteracts cell-cell adhesions rendering widened intercellular junction. The contractile force is generated on the basis of actin-myosin binding triggered by phosphorylation of myosin light chain (MLC), the major substrate of MLC kinase (MLCK). Myocin light chain kinase phosphorylates MLC at Ser19/Thr18, leading to a conforma-tional change in the myosin tertiary structure that triggers actomyosin contraction. 3 The nonmuscle MLCK (nmMLCK, Ϸ220 kilodalton) is the predominant isoform in the endothelium of human macro/ microvessels. 4 This isoform and the short smooth muscle isoform (Ϸ108 kilodalton) are encoded by the same mylk1 gene but different promoters. [5] [6] [7] A role of nmMLCK in regulating various cellular responses has recently been documented. 8 -14 Consistent with its function in cell contraction, nmMLCK contributes to endothelial cell-cell junction opening and paracellular hyperpermeability in response to proinflammatory agents such as histamine, 15 thrombin, 16 oxygen radicals, 17 and activated neutrophils. 18 Moreover, nmMLCK participates in inflammation by promoting neutrophil transendothelial migration 19 and by activating nuclear factor B (NF-B) 20 and cytokine production. 21 Nonmuscle myosin light-chain kinase also plays a role in nitrosative stress during endotoxin shock. 11 The pathophysiological importance of nmMLCK in inflammation is further supported by studies with genetically modified animals. In particular, nmMLCK isoform-specific knockout (nmmlck Ϫ/Ϫ ) produces a phenotype indistinguishable from the wild type without major cardiovascular defects; 13, 22 however, nmMLCK deletion confers decreased susceptibility to acute lung injury 13 and improved survival in endotoxic shock 11 and severe burns. 12 During atherosclerosis development, endothelial barriers undergo conformational or structural changes promoting lipoprotein and leukocyte transendothelial flux and deposition in the vascular wall. Several proinflammatory mediators, including thrombin, oxidized low-density lipoprotein (ox-LDL) and tumor necrosis factor ␣ (TNF-␣), have been identified as contributors to atherosclerotic lesions; however, the molecular mechanisms underlying their injurious effects have not been characterized. On the basis of our recent finding that nmMLCK mediates vascular hyperpermeability in systemic inflammation, 12, 23, 24 we hypothesize that nmMLCK contributes to atherosclerosis by altering endothelial barrier function and promoting monocyte infiltration. We tested this hypothesis using an apoE-deficient murine model of atherosclerosis.
Methods
Additional details are available in the online-only Data Supplement.
ApoE ؊/؊ nmmlck ؊/؊ Mice Generation and Atherosclerosis Characterization
Apolipoprotein E-deficient mice and nmmlck Ϫ/Ϫ mice were used to generate apoE Ϫ/Ϫ nmmlck ϩ/ϩ (nϭ11) and apoE Ϫ/Ϫ nmmlck Ϫ/Ϫ (nϭ13) mice (online-only Data Supplement Figure I ). Atherosclerosis was induced by feeding male mice at 6 weeks of age an atherogenic diet (Research Diet, New Brunswick, NJ) for 12 weeks. To assess lesion, heart-aorta complexes were excised. Thoracicabdominal aortas were fixed with 10% formalin, and aortic sinuses and arches were embedded for frozen sectioning. All animal procedures were conducted in compliance with National Institutes of Health guidelines and approved by the institutional animal care and use committee.
Primary Culture of Aortic Endothelial Cells
Primary aortic endothelial cells (AECs) were isolated from mice using positive immuno-selection with a rat antimouse CD31.
Monocyte Isolation and Transmigration
Murine peripheral monocytes were separated via histopaque (Sigma, MO) gradient centrifugation followed by negative selection (Stem Cell, British Columbia, Canada). Transendothelial migration was examined as previously described 25 with modifications.
In Vitro and In Vivo Permeability Assays
As an indicator of barrier properties, transendothelial electric resistance (TER) was measured following a previously described procedure. 25 In vivo vascular barrier function was examined with a modified Evans blue assay. 26 
Statistical Analysis
For the vascular pathologies (eg, atherosclerotic lesion size, intimal hyperplasia, and macrophage infiltration), comparisons were made between 13 nmmlck Ϫ/Ϫ and 11 nmmlck ϩ/ϩ mice. For the cell studies, at least 3 independent experiments from different samples were performed under each condition, where repeated measurements from each sample were averaged and counted as 1 experiment. Data were presented as meanϮSE. Unpaired t test was employed for comparisons between 2 groups. For comparisons among multiple groups, 1or 2-way ANOVA was used followed by the Newman-Keuls test. Significance was accepted at PՅ0.05.
Results

Absence of Nonmuscle Myosin Light-Chain Kinase Reduces Atherosclerosis in apoE ؊/؊ Mice
Compared with apoE Ϫ/Ϫ nmmlck ϩ/ϩ littermates, apoE Ϫ/Ϫ nmmlck Ϫ/Ϫ mice displayed no change in food consumption, weight, and fertility; however, they showed a 53% reduction in the area of thoracic-abdominal lesion ( Figure 1A) after an atherogenic diet for 12 weeks. A similar reduction was found in the intimal area of aortic sinus cross-sections ( Figure 1B ) and aortic arch longitudinal sections ( Figure  1C ) from apoE Ϫ/Ϫ nmmlck Ϫ/Ϫ mice. Lipid deposition in the lesion, as demonstrated by Oil Red O-positive region, was decreased by 44% in the aortic arch and 31% in the aortic sinus from apoE Ϫ/Ϫ nmmlck Ϫ/Ϫ mice ( Figure 1B and 1C). The absence of nmMLCK did not significantly change the serum concentration of lipids, including triglyceride and total, LDL, high-density lipoprotein and very lowdensity lipoprotein cholesterol (online-only Data Supplement Table I ).
Absence of Nonmuscle Myosin Light-Chain Kinase Alters Cell and Collagen Contents in the Intima
Consistent with reduced lesion size, decreased macrophage content was observed in the intima of nmMLCK-deficient aorta (40% reduction, Figure 2A ). Although there was no significant change of T cells in the plaque (online-only Data Supplement Figure IIA ), there was a 95% increase in smooth muscle cells (SMCs) ( Figure 2B ) and a 65% increase in collagen deposition ( Figure 2C ) in apoE Ϫ/Ϫ nmmlck Ϫ/Ϫ compared to apoE Ϫ/Ϫ nmmlck ϩ/ϩ mice.
Nonmuscle Myosin Light-Chain Kinase Deficiency Attenuates Inflammation-Induced Endothelial Barrier Dysfunction
We compared the effects of oxLDL and thrombin on endothelial permeability with or without nmMLCK. Aortic ECs were isolated from nmmlck Ϫ/Ϫ and nmmlck ϩ/ϩ mice, and nmMLCK expression in these cells was confirmed by reverse-trascriptase polymerase chain reaction (RT-PCR) and Western blotting ( Figure 3B and 3C ). An electric cell-substrate impedance sensor was used to measure the dynamic changes in TER, an indicator of endothelial barrier function. Deficiency of nmMLCK attenuated both thrombin-and oxLDL-caused TER reduction ( Figure 3D and 3E), suggest- ing that nmMLCK contributes to the endothelial barrier response to these inflammatory mediators.
We further assessed albumin transport across the vascular wall in vivo using Evans blue assay. 26 There was no difference between nmmlck Ϫ/Ϫ and nmmlck ϩ/ϩ in apoE ϩ/ϩ mice; however, in apoE Ϫ/Ϫ mice, absence of nmMLCK resulted in a 35% reduction in Evans blue deposition in the aorta compared with nmmlck ϩ/ϩ littermates ( Figure 3F ). Additional experiments demonstrated a small but significantly higher Evans blue staining in apoE Ϫ/Ϫ mice compared with the wild type ( Figure 3G ). These findings, consistent with the normal phenotype of nmmlck Ϫ/Ϫ mice, suggest that nmMLCK plays an important role in the pathophysiological regulation of endothelial barriers.
Absence of Nonmuscle Myosin Light-Chain Kinase Reduces Monocyte Transmigration
Monocytes were isolated from the peripheral blood of nmmlck ϩ/ϩ or nmmlck Ϫ/Ϫ mice, and their transmigration across nmmlck ϩ/ϩ or nmmlck Ϫ/Ϫ endothelial monolayers to a monocyte chemoattractant protein (MCP-1) was examined.
Knockout of nmMLCK in ECs did not significantly reduce monocyte transmigration (data not shown); however, nmmlck Ϫ/Ϫ monocytes displayed significantly impaired transmigration in the presence or absence of nmmlck ϩ/ϩ endothelial monolayers ( Figure 4A ). The data suggest that monocytic nmMLCK is relatively more important than endothelial nmMLCK in regulating monocyte motility. Consistently, nmMLCK messenger RNA and protein were detected in monocytes ( Figure 4B ). To the best of our knowledge, this is the first report on nmMLCK expression in monocytes.
Both Myosin Light-Chain Kinase and Nonkinase Activities Contribute to Endothelial Barrier Dysfunction and Monocyte Transmigration
To determine the mechanisms of nmMLCK function, we tested the involvement of MLCK kinase activity-coupled MLC phosphorylation in response to LDL or thrombin. Although native LDL did not cause significant MLC phosphorylation or TER reduction (online-only Data Supplement Figure III ), oxLDL promoted MLC phosphorylation in ECs over the same time course as TER reduction, and the phosphorylation was diminished in the absence of nmMLCK ( Figure  5A ). ML-7 (1-[5-Iodonaphthalene-1sulfonyl]homopiperazine), a pan-inhibitor of MLC kinases, attenuated oxLDL-induced hyperpermeability response (Figure 5B ). In parallel, we compared the effects of thrombin on TER and MLC phosphorylation in nmmlck ϩ/ϩ and nmmlck Ϫ/Ϫ ECs. The TER response was attenuated in nmmlck Ϫ/Ϫ whereas MLC phosphorylation was detected at the same level in the 2 cell types ( Figure 5C ), suggesting that thrombin-induced hyperpermeability involves mechanisms that are uncoupled with MLC phosphorylation. Additional experiments demonstrated that MLC phosphorylation is not required for monocyte motility regardless of nmMLCK presence ( Figure 5D ).
Nonmuscle Myosin Light-Chain Kinase Contributes to Src Activation Independently of Kinase Activity
We then examined the mitogen-activated protein kinase (MAPK), NF-B, and Rous sacracoma virus homolog genesencoded tyrosine kinases (Src) pathways as potential signals downstream from nmMLCK. In aortic ECs, neither thrombin nor oxLDL induced detectable phosphorylation of NF-B p65 at Ser536 (indicator of activation) (online-only Data Supplement Figure IVA) . Although thrombin increased phosphorylation of p38 MAPK, extracellular signal-regulated kinase 1/2, and stress-activated Protein Kinase/c-Jun kinase (online-only Data Supplement Figure IVB) , the responses were not different in nmmlck ϩ/ϩ and nmmlck Ϫ/Ϫ cells. In contrast, Src phosphorylation was different in that increased Src phosphorylation at tyrosine 416 in thrombin-treated ECs ( Figure 6A ) and in MCP-1-treated monocytes ( Figure 6C ) was attenuated by nmMLCK deficiency. Neither thrombin nor MCP-1 induced Src phosphorylation at tyrosine 527, indicating residue-specific activation. ML-7, an inhibitor of MLC phosphorylation (online-only Data Supplement Figure  V) , failed to alter Src phosphorylation ( Figure 6B and 6D) , further supporting that nmMLCK-mediated Src activation is not dependent on its kinase activity or MLC phosphorylation.
Nonmuscle Myosin Light-Chain Kinase-Src Pathway Mediates Endothelial Barrier Dysfunction and Monocyte Transmigration
The signaling role of Src in regulating endothelial barrier function and monocyte transmigration is further tested in the following Src manipulation experiments. Pharmacological inhibition of Src activation with 4-Amino-5-(4chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2) ( Figure 7A ), overexpressing the Src endogenous inhibitor C-terminal Src kinase (Csk) ( Figure 7B ), or Src gene silencing via small interfering RNA (siRNA) knockdown ( Figure  7C ) attenuated thrombin-induced TER reduction in ECs. However, the same treatment did not significantly alter MLC phosphorylation to thrombin (online-only Data Supplement Figure VIA) . To specify the cause-effect relationship between Src phosphorylation and barrier dysfunction, murine ECs were cotransfected with siRNA specific for murine Src and pCMV6/human Src. Mismatches between mouse and human Src gene sequences ( Figure 7D , panel II) led to the rescue expression of Src ( Figure 7D , panel I). Consistently, wildtype Src, but not the Y416A mutant Src, restored the TER response ( Figure 7D , panel I, and 7D, panel III), indicating the specific role of Src activation via Y416 phosphorylation in mediating endothelial barrier dysfunction.
In monocytes, pretreatment with PP2 reduced their transendothelial migration ( Figure 8A ). Further studies using human acute monocytic leukemia cell line (THP-1) cells confirmed the constitutive expression of human nmMLCK and successful knockdown by siRNA in these cells ( Figure 8B ). Consistent with the findings from murine monocytes, depletion of nmMLCK in THP-1 attenuated Src phosphorylation ( Figure  8C ) and transendothelial migration in response to MCP-1 ( Figure 8E ). Further, THP-1 cells were transfected with siRNA specific to human Src ( Figure 8D ) and pCMV6/Csk ( Figure 8F ). Both interventions significantly reduced THP-1 transendothelial migration ( Figure 8E and 8F ).
Discussion
Although nmMLCK is implicated in endothelial dysfunction caused by various inflammatory mediators, 11, 12, 13 its specific role in atherosclerosis has not been reported. This study provides direct evidence for the involvement of nmMLCK in atherosclerotic lesion development. The beneficial effect of nmMLCK on atherosclerosis may involve 3 major cell types identified in atheroma: ECs, monocytes, and SMCs. In ECs, nmMLCK is the predominant MLCK isoform that triggers actomyosin contraction, and its causal effect on the paracel- lular permeability response to proinflammatory or prothrombotic agonists has been well documented. 15, 16, 17 Consistently, inhibition of MLCK kinase activity or genetic deletion of nmMLCK leads to beneficial effects against microvascular leakage, 23,24 acute lung injury, 13 endotoxic shock, 11 and severe burns. 12 In line with these findings, our results demonstrate that nmMLCK knockout or inhibition attenuates endothelial hyperpermeability to TNF-␣ (online-only Data Supplement Figure VII) , thrombin and oxLDL, proinflammatory mediators associated with atherosclerosis.
The barrier property of ECs also affects leukocyte diapedesis. On the basis of the theory that disruption of endothelial cell-cell junctions facilitates leukocyte transmigration, 27 we hypothesized that nmMLCK deficiency would disable EC contractile machinery, thereby impairing junction opening for leukocytes to move through. To our surprise, however, nmMLCK knockout in ECs attenuated endothelial hyperpermeability without significantly altering monocyte transmigration. On the other hand, nmmlck Ϫ/Ϫ monocytes showed impaired migration activity. Thus, the decreased monocyte infiltration into the atherosclerotic lesion observed in apoE Ϫ/Ϫ nmmlck Ϫ/Ϫ mice was mainly attributed to impaired motility of monocytes lacking nmMLCK. This finding indicates the complexity of leukocyte-endothelium interactions, processes controlled by both leukocyte activity and endothelial function. Indeed, endothelial hyperpermeability and leukocyte transmigration are not always coupled, and spatial or temporal dissociation between the 2 events has been frequently observed. 28 Another interesting aspect of this study is the constitutive expression of nmMLCK in both human and murine mono-cytes. The nmMLCK isoform, once named endothelial MLCK, 4 is thought to be expressed predominantly in ECs. The presence of nmMLCK in monocytes and its functional role in monocyte infiltration indicate the therapeutic potential of targeting this isoform for treating immunologic disorders or inflammatory diseases. Although detected in both ECs and monocytes, nmMLCK is expressed in the vascular smooth muscle at a minimal level. 4 In this study, we observed an increased SMC content in the atherosclerotic lesion of apoE Ϫ/Ϫ nmmlck Ϫ/Ϫ mice. Although it remains unclear whether nmMLCK deficiency affects SMC function or changes local environments within the atheroma, 29 its effect to increase SMC contents in the plaque may be beneficial during the progress of atherosclerosis. Decreased macrophage content is usually, if not always, coupled with a higher level of SMC migration into the intima and thus more collagen deposition in the lesion, 30 leading to stabilized plaques that are less susceptible to rupture. 31 With respect to the molecular mechanisms by which nmMLCK mediates endothelial barrier dysfunction and monocyte migration, MLCK is traditionally thought to function exclusively through its kinase activity. Myosin lightchain kinase-catalyzed MLC phosphorylation and resultant actomyosin contraction is considered the major mechanism of intercellular gap formation in response to hyperpermeability factors like histamine, 15 thrombin, 16 oxygen radicals, 17 and activated neutrophils. 18 Inhibition of MLCK kinase activity attenuates microvascular leakage induced by phorbol esters, 23 neutrophils, 24 and septic agents. 13 Consistently, a MLC phosphorylation-coupled barrier response was seen in the current study with ECs exposed to oxLDL. Emerging evidence suggests the involvement of MLC phosphorylation-uncoupled mechanisms in nmMLCKmediated cellular events. For example, nmMLCK can alter endothelial calcium entry independently of its kinase activity. 32 Telokin, a small MLCK isoform lacking the catalytic domain, regulates calcium sensitivity through activation of MLCP. 33 Most recently, nmMLCK is found to promote neutrophil infiltration into septic lungs, 34 an effect involving proline-rich tyrosine kinase 2 activation and independent of MLC phosphorylation. In line with these findings, our data showed that in ECs, nmMLCK deficiency attenuated thrombin-induced hyperpermeability without altering its substrate activity, because a comparable MLC phosphorylation level was observed between nmmlck Ϫ/Ϫ and nmmlck ϩ/ϩ cells ( Figure 5C ). The data suggest that nmMLCK can mediate endothelial barrier responses to different agonists (oxLDL versus thrombin) via different mechanisms (kinase dependent or independent). Moreover, although nmMLCK deficiency significantly reduced monocyte migration to MCP-1, MLC phosphorylation was not detectable in either nmmlck Ϫ/Ϫ or nmmlck ϩ/ϩ monocytes. Thus, nmMLCK mediates multiple cellular responses where MLC phosphorylation is not a prerequisite or necessarily coupled event. It is noted that ML-7, a pan-MLCK inhibitor, was able to attenuate the barrier dysfunction and block MLC phosphorylation to thrombin (online-only Data Supplement Figure V) . In another study, the same drug significantly reduced the basal permeability of microvessels in the absence of thrombin. 23 To characterize nmMLCK downstream signaling independent of MLC phosphorylation, we examined MAPK, NF-kB and Src pathways, which are known to regulate vascular inflammation. Although MAPK activation has been identified as a common step in endothelial and monocytic responses to a wide spectrum of physiological and pathological factors, 35 it did not seem to be a key event in thrombin-nmMLCK signaling, given that the activation levels of p38, extracellular we did not detect NF-B phosphorylation to either thrombin or oxLDL regardless of nmMLCK presence. Therefore, NF-B may be relatively less important in thrombin-and oxLDL-induced responses.
Interestingly, Src phosphorylation at Tyr416 in thrombintreated ECs and MCP-1-treated monocytes was greatly attenuated in the absence of nmMLCK. The binding and signaling interactions between nmMLCK and Src is supported by the molecular structure of nmMLCK characterized by a N-terminus containing multiple sites for protein-protein interactions, including several Src homology domain 2/domain 3-binding consensus sequences and 3 potential sites for Src phosphorylation. 36, 37 Recent studies have demonstrated the ability of nmMLCK to bind Src 36 and regulate its kinase activity through phosphorylation. 38 The possibility that Src serves as a key signal in nmMLCK-mediated monocyte activity and EC function is further supported by the fact that Src controls integrin-dependent leukocyte mobility 39 and that Src mediates MCP-1-induced monocyte transendothelial migration. 35 Moreover, Src-induced protein tyrosine phosphorylation plays an important role in regulating endothelial junction structure 40 and function. 16 The failure of ML-7 to inhibit Src phosphorylation has further confirmed the kinaseindependence of the nmMLCK-Src pathway. In the current study, pharmacological inhibition of Src, molecular manipulation of Src via knockdown, or overexpressing Csk significantly attenuated the endothelial barrier response to thrombin. In monocytes, Src knockdown, nmMLCK depletion, or Csk overexpression impaired their transendothelial migration. Rescue experiments further demonstrated that wild-type Src, but not SrcY416A mutant, recovered the hyperpermeability response, confirming the specific importance of tyrosine 416 in Src-mediated cellular events. Taken together, these experiments support the causal effects of Src activation on nmMLCK-mediated endothelial hyperpermeability and monocyte transmigration in response to proatherogenic factors. Src signaling is likely located downstream of nmMLCK because nmMLCK knockout can block Src activation whereas inhibition of Src failed to affect nmMLCK activity (online-only Data Supplement Figure VI) .
In conclusion, this study demonstrates a pathophysiological role of nmMLCK in atherogenesis. We suggest that nmMLCK participates in atherosclerotic lesion development by augmenting endothelial barrier dysfunction and monocyte infiltration in response to proinflammatory factors, including thrombin, oxLDL, and TNF-␣. The molecular mechanisms of nmMLCK-mediated cellular responses involve not only kinase-dependent MLC phosphorylation but also Src signaling that is independent of MLC phosphorylation. This work has shed light on, as well as raised questions about, the diverse cellular and molecular effects of nmMLCK. Given the finding that nmMLCK is dispensable in physiological conditions 13 but required for the action of certain proatherogenic factors, selective blockage of this isoform may represent a new area of drug development for the treatment of atherosclerosis.
